Outpatient cross-titration to buprenorphine for chronic pain: A retrospective analysis

Satoru Ito; Mackenzie Welsh; Christina Bockman; Rebecca Dale; David Pilkington; Katherin Peperzak

doi:10.5055/jom.0839

Authors

Satoru Ito, PharmD, BCPS
Mackenzie Welsh, PharmD
Christina Bockman, PharmD
Rebecca Dale, DO
David Pilkington, DO
Katherin Peperzak, MD

DOI:

https://doi.org/10.5055/jom.0839

Keywords:

buprenorphine, buprenorphine, naloxone drug, combination, chronic pain, analgesics, opioid, buprenorphine cross-titration

Abstract

Objective: To determine the effectiveness and safety of the University of Washington's buprenorphine cross-titration protocol for chronic pain in the outpatient setting.

Methods: Retrospective chart review was performed on 150 patients transitioned from full μ-opioid agonist therapy to buprenorphine using the University of Washington Medical Center Pain Clinic's cross-titration protocol between September 1, 2020, and December 31, 2021, in an outpatient setting. Primary outcome was to determine the percentage of patients who completed the cross-titration and continued buprenorphine without full μ-opioid agonists 4 weeks after completion. Secondary outcomes included final buprenorphine dose, days needed to complete cross-titration, deviation rates from the protocol, and opioid-related adverse events.

Results: Fifteen of 31 (48.4 percent) included patients successfully converted to buprenorphine. Median duration of successful cross-titration was 29 days (interquartile range 19-57). Average end-titration dose for patients on buprenorphine/naloxone sublingual films was 7.9 ± 5.7 mg/day, while for buprenorphine transdermal (TD) patches, it was 11.9 ± 4.8 mcg/h. Morphine equivalent daily dose (MEDD) prior to induction varied widely. All patients transitioned to TD buprenorphine were taking ≤30 mg MEDD. Patients previously taking >120 mg MEDD stabilized on 8-16 mg/day buprenorphine. Most common reasons for cross-titration failure were inadequate pain control and intolerable adverse effects.

Discussion: The University of Washington's buprenorphine cross-titration protocol for chronic pain was successful in about half of included patients undergoing conversion from chronic full μ-opioid agonist therapy and generally well tolerated. Clinical responses were widely variable, and many required slower taper and higher end-titration buprenorphine dose than anticipated. Although protocols provide structure for cross-titration, each course should be monitored closely and individualized.

Author Biographies

Satoru Ito, PharmD, BCPS

Department of Pharmacy Services, University of Washington Medicine, Seattle, Washington

Mackenzie Welsh, PharmD

Department of Pharmacy Services, University of Washington Medicine, Seattle, Washington

Christina Bockman, PharmD

Department of Pharmacy Services, University of Washington Medicine, Seattle, Washington

Rebecca Dale, DO

Department of Anesthesia and Pain Medicine, University of Washington Center for Pain Relief, Seattle, Washington

David Pilkington, DO

Department of Rehabilitation Medicine, University of Washington, Seattle, Washington

Katherin Peperzak, MD

Department of Anesthesia and Pain Medicine, University of Washington Center for Pain Relief, Seattle, Washington

References

Dahlhamer J, Lucas J, Zelaya C, et al.: Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. MMWR Morb Mortal Wkly Rep. 2018; 67(36): 1001-1006. DOI: 10.15585/mmwr.mm6736a2. DOI: https://doi.org/10.15585/mmwr.mm6736a2

Aiyer R, Gulati A, Gungor S, et al.: Treatment of chronic pain with various buprenorphine formulations. Anesth Analg. 2018; 127(2): 529-538. DOI: 10.1213/ane.0000000000002718. DOI: https://doi.org/10.1213/ANE.0000000000002718

Lazaridou A, Paschali M, Edwards RR, et al.: Is buprenorphine effective for chronic pain? A systematic review and meta-analysis. Pain Med. 2020; 21(12): 3691-3699. DOI: 10.1093/pm/pnaa089. DOI: https://doi.org/10.1093/pm/pnaa089

Hale M, Garofoli M, Raffa RB: Benefit-risk analysis of buprenorphine for pain management. JPR. 2021; 14: 1359-1369. DOI: 10.2147/jpr.s305146. DOI: https://doi.org/10.2147/JPR.S305146

Gudin J, Fudin J: A narrative pharmacological review of buprenorphine: A unique opioid for the treatment of chronic pain. Pain Ther. 2020; 9(1): 41-54. DOI: 10.1007/s40122-019-00143-6. DOI: https://doi.org/10.1007/s40122-019-00143-6

Dahan A, Yassen A, Romberg R, et al.: Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006; 96(5): 627-632. DOI: 10.1093/bja/ael051. DOI: https://doi.org/10.1093/bja/ael051

Case AA, Kullgren J, Anwar S, et al.: Treating chronic pain with buprenorphine—The practical guide. Curr Treat Options Oncol. 2021; 22(12): 116. DOI: 10.1007/s11864-021-00910-8. DOI: https://doi.org/10.1007/s11864-021-00910-8

Ballantyne JC: Opioid therapy in chronic pain. Phys Med Rehabil Clin N Am. 2015; 26(2): 201-218. DOI: 10.1016/j.pmr.2014.12.001. DOI: https://doi.org/10.1016/j.pmr.2014.12.001

Pergolizzi J, Böger RH, Budd K, et al.: Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Practice. 2008; 8(4): 287-313. DOI: 10.1111/j.1533-2500.2008.00204.x DOI: https://doi.org/10.1111/j.1533-2500.2008.00204.x

US Department of Health and Human Services: Pain management best practices inter-agency task force report: Updates, gaps, inconsistencies, and recommendations. 2019. Available at https://www.hss.gov/ash/advisory-committees/pain/reports/index.html. Accessed December 19, 2021.

Indivior Inc.: Suboxone (Buprenorphine/Naloxone) [Prescribing Information]. North Chesterfield, VA: Indivior Inc., 2021.

BioDelivery Sciences International, Inc.: Belbuca (Buprenorphine) [Prescribing Information]. Raleigh, NC: BioDelivery Sciences International, Inc., 2021.

Purdue Pharma LP: Butrans (Buprenorphine) [Prescribing Information]. Stamford, CT: Purdue Pharma LP, 2021. 14. Webster L, Gudin J, Raffa RB, et al.: Understanding buprenorphine for use in chronic pain: Expert opinion. Pain Med. 2020; 21(4): 714-723. DOI: 10.1093/pm/pnz356. DOI: https://doi.org/10.1093/pm/pnz356

Hämmig R, Kemter A, Strasser J, et al.: Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method. Subst Abuse Rehabil. 2016; 7: 99-105. DOI: 10.2147/SAR.S109919. DOI: https://doi.org/10.2147/SAR.S109919

Rozylo J, Mitchell K, Nikoo M, et al.: Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. Addict Sci Clin Pract. 2020; 15(1). DOI: 10.1186/s13722-020-0177-x. DOI: https://doi.org/10.1186/s13722-020-0177-x

Terasaki D, Smith C, Calcaterra SL: Transitioning hospitalized patients with opioid use disorder from methadone to buprenorphine without a period of opioid abstinence using a microdosing protocol. Pharmacotherapy. 2019; 39(10): 1023-1029. DOI: 10.1002/phar.2313. DOI: https://doi.org/10.1002/phar.2313

Ahmed S, Bhivandkar S, Lonergan BB, et al.: Microinduction of buprenorphine/naloxone: A review of the literature. Am J Addict. 2021; 30(4): 305-315. DOI: 10.1111/ajad.13135. DOI: https://doi.org/10.1111/ajad.13135

Becker WC, Frank JW, Edens EL: Switching from high-dose, long-term opioids to buprenorphine: A case series. Ann Intern Med. 2020; 173(1): 70-71. DOI: 10.7326/l19-0725. DOI: https://doi.org/10.7326/L19-0725

Gimbel J, Spierings ELH, Katz N, et al.: Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain. Pain. 2016; 157(11): 2517-2526. DOI: 10.1097/j.pain.0000000000000670. DOI: https://doi.org/10.1097/j.pain.0000000000000670

Steiner D, Munera C, Hale M, et al.: Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: A randomized, double-blind study. J Pain. 2011; 12(11): 1163-1173. DOI: 10.1016/j.jpain.2011.06.003. DOI: https://doi.org/10.1016/j.jpain.2011.06.003

Zimmerman A, Bikdash R, Rauck R: Conversion of schedule II opioids to buprenorphine buccal film: A retrospective analysis. Pain Med. 2021; 22(5): 1109-1115. DOI: 10.1093/pm/pnaa226. DOI: https://doi.org/10.1093/pm/pnaa226

Webster L, Gruener D, Kirby T, et al.: Evaluation of the tolerability of switching patients on chronic full μ-opioid agonist therapy to buccal buprenorphine. Pain Med. 2016; 17(5): pnv110-pnv907. DOI: 10.1093/pm/pnv11. DOI: https://doi.org/10.1093/pm/pnv110

Freye E, Anderson-Hillemacher A, Ritzdorf I, et al.: Opioid rotation from high-dose morphine to transdermal buprenorphine (transtec) in chronic pain patients. Pain Practice. 2007; 7(2): 123-129. DOI: 10.1111/j.1533-2500.2007.00119.x. DOI: https://doi.org/10.1111/j.1533-2500.2007.00119.x

Lee DS, Hann JE, Klaire SS, et al.: Rapid induction of buprenorphine/naloxone for chronic pain using a microdosing regimen: A case report. A A Practice. 2020; 14(2): 44-47. DOI: 10.1213/XAA.0000000000001138. DOI: https://doi.org/10.1213/XAA.0000000000001138

Sandhu R, Zivanovic R, Klaire S, et al.: Buprenorphine/ naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: A case report. Can J Pain. 2019; 3(1): 79-84. DOI: 10.1080/24740527.2019.1599279. DOI: https://doi.org/10.1080/24740527.2019.1599279